1[1]Bertazzoli C,Rovero C,Ballerini L,et al. Experimental systemic toxicology of 4′ epidoxorubicin:A new less cardiotoxic anthracycline antitumour agent.Toxicol Appl Pharmacol, 1985,79:412-422.
2[2]Praga C,Trave F,Petroccione A.Anthracycline-induced cardiotoxicityand its relevance in cancer treatment. In:Nimmo WS,Tucker GT,eds.Clinical Measurement in Drug Evaluation. London:Wolfe Publishing,1991.131-142.
3[3]Martonin A,Giovannini M,Tomasi L,et al.Pannutif:a phase Ⅱ clinical trial of 4′-epidoxorubicin in advanced solid tumors. Cancer Chemother Pharmacol,1984,12:179.
4[4]Mouridsen HT. New cytotoxic drugs in treatment of breast cancer.Acta Oncol, 1990,29:343-347.
5[5]Delozicer T,Vernhes JC. Etude comparative de I′adriamycine, et la mitoxantrone dans le cancer du sein:Revue de la literatuer. Bull Cancer, 1991,78:1013-1025.
6[6]Lewis AB,Crouse VI, Evans W, et al. Recovery of left ventricular function following discontinuation of anthracycline chemotherapy in children. Pediatrics, 1981,68:67-72.
7[7]Goorin AM, Borow KM,Goldman A, et al. Congestive heart failure due to adriamycin cardiotoxicity:its natural history in children. Cancer , 1981,47:2810-2816.
8[8]Twelves C, Dobbs N, Summers, L, et al. Pharmacokinetics of epirubicin(EPI) in patients with abnormal liver biochemistry. Br J Cancer, 1990,62:528-529.
9[9]Dobbs NA, Twelves C J, Gillies H, et al. Comparative pharmacokine tics and metabolism of doxorubicin(DOX) and epidoxorubciin(EPI) in relation to liver biochemistry tests. Br J Cancer, 1991,63 (Suppl 13):46.
